Endothelium-derived relaxant factor inhibits platelet activation - PubMed (original) (raw)

. 1987 Nov;336(5):566-71.

doi: 10.1007/BF00169315.

Affiliations

• PMID: 2830546
• DOI: 10.1007/BF00169315

Endothelium-derived relaxant factor inhibits platelet activation

R Busse et al. Naunyn Schmiedebergs Arch Pharmacol. 1987 Nov.

Abstract

Experiments were designed to investigate whether platelet activation is modulated by endothelium-derived relaxant factor (EDRF) which has been shown to induce vascular smooth muscle relaxation by direct stimulation of soluble guanylate cyclase. EDRF was released from cultured bovine endothelial cells, grown on microcarrier beads, by stimulation with thimerosal in the presence of indomethacin. EDRF had no effect on the intracellular free calcium concentration (Cai2+, measured with the fluorescent indicator indo-1) of resting washed human platelets but significantly attenuated the thrombin-induced rise of Cai2+ from 896 +/- 99 (SEM) to 509 +/- 48 nmol/l. EDRF significantly increased platelet cyclic GMP levels from 0.25 +/- 0.04 to 2.5 +/- 0.4 pmol/10(8) platelets and reduced the thrombin-induced aggregation to 23 +/- 3% of control. EDRF had no effect on Cai2+, cyclic GMP or aggregation after a 3 min storage interval, but superoxide dismutase (shown to increase stability of the labile factor) significantly augmented the EDRF effects on Cai2+. The antiaggregatory potency of EDRF was completely abolished in the presence of hemoglobin. The results characterize EDRF as a potent cyclic GMP-dependent antiaggregatory factor which may act synergistically in vivo with the cyclic AMP-dependent inhibitory effect of prostacyclin.

PubMed Disclaimer

Similar articles

• LY 83583 (6-anilino-5,8-quinolinedione) blocks nitrovasodilator-induced cyclic GMP increases and inhibition of platelet activation.
  Mülsch A, Lückhoff A, Pohl U, Busse R, Bassenge E. Mülsch A, et al. Naunyn Schmiedebergs Arch Pharmacol. 1989 Jul;340(1):119-25. doi: 10.1007/BF00169217. Naunyn Schmiedebergs Arch Pharmacol. 1989. PMID: 2552329
• Human endothelial cells inhibit platelet aggregation by separately stimulating platelet cyclic AMP and cyclic GMP.
  Alheid U, Reichwehr I, Förstermann U. Alheid U, et al. Eur J Pharmacol. 1989 May 2;164(1):103-10. doi: 10.1016/0014-2999(89)90236-7. Eur J Pharmacol. 1989. PMID: 2546782
• Endothelium-derived relaxing factor from cultured human endothelial cells inhibits aggregation of human platelets.
  Alheid U, Frölich JC, Förstermann U. Alheid U, et al. Thromb Res. 1987 Sep 1;47(5):561-71. doi: 10.1016/0049-3848(87)90361-6. Thromb Res. 1987. PMID: 3499684
• Antiplatelet effects of endothelium-derived relaxing factor and nitric oxide donors.
  Bassenge E. Bassenge E. Eur Heart J. 1991 Nov;12 Suppl E:12-5. doi: 10.1093/eurheartj/12.suppl_e.12. Eur Heart J. 1991. PMID: 1665128 Review.
• Platelet-derived serotonin, the endothelium, and cardiovascular disease.
  Vanhoutte PM. Vanhoutte PM. J Cardiovasc Pharmacol. 1991;17 Suppl 5:S6-12. J Cardiovasc Pharmacol. 1991. PMID: 1717775 Review.

Cited by

• Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.
  Beckman JS, Beckman TW, Chen J, Marshall PA, Freeman BA. Beckman JS, et al. Proc Natl Acad Sci U S A. 1990 Feb;87(4):1620-4. doi: 10.1073/pnas.87.4.1620. Proc Natl Acad Sci U S A. 1990. PMID: 2154753 Free PMC article.
• Regulation of platelet granule exocytosis by S-nitrosylation.
  Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM 3rd, Faraday N, Lowenstein CJ. Morrell CN, et al. Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3782-7. doi: 10.1073/pnas.0408310102. Epub 2005 Feb 28. Proc Natl Acad Sci U S A. 2005. PMID: 15738422 Free PMC article.
• Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide.
  Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka CB, Murthy SN, Nossaman BD, Kadowitz PJ. Badejo AM Jr, et al. Am J Physiol Heart Circ Physiol. 2010 Oct;299(4):H1153-9. doi: 10.1152/ajpheart.01101.2009. Epub 2010 Jul 16. Am J Physiol Heart Circ Physiol. 2010. PMID: 20639220 Free PMC article.
• Platelet inhibition by endothelium-derived relaxing factor from the rabbit perfused aorta.
  Bult H, Fret HR, Van den Bossche RM, Herman AG. Bult H, et al. Br J Pharmacol. 1988 Dec;95(4):1308-14. doi: 10.1111/j.1476-5381.1988.tb11769.x. Br J Pharmacol. 1988. PMID: 3064856 Free PMC article.
• The effect of endothelium-derived nitric oxide on ex vivo whole blood platelet aggregation in man.
  Vallance P, Benjamin N, Collier J. Vallance P, et al. Eur J Clin Pharmacol. 1992;42(1):37-41. doi: 10.1007/BF00314917. Eur J Clin Pharmacol. 1992. PMID: 1541315

References

1. 1. J Pharmacol Exp Ther. 1986 Jul;238(1):352-9 - PubMed
2. 1. J Pharmacol Exp Ther. 1982 Jan;220(1):183-90 - PubMed
3. 1. Biochem Biophys Res Commun. 1981 Jul 16;101(1):61-7 - PubMed
4. 1. J Pharmacol Exp Ther. 1985 Mar;232(3):708-16 - PubMed
5. 1. Circ Res. 1983 Nov;53(5):557-73 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal